Tulsa, Oklahoma 74133

  • Pancreatic Cancer


To assess the ability of a combination of updated and approved modalities in the treatment of first line pancreatic cancer patients to increase the time to Progression Free Survival

Study summary:

For resectable patient; surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery. For marginally resectable patients; the patients will have 2-3 cycles of neoadjuvant chemotherapy of FOLFIRINOX and then restaged, undergo surgery with IORT within 2-4 weeks following chemotherapy. Then radiation therapy starting within 6-8 weeks. Followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles.


Inclusion Criteria: - Histologically proven Exocrine Adenocarcinoma of the pancreas - Clinically resectable or marginally resectable disease - No prior radiation or chemotherapy for carcinoma of the pancreas - ECOG performance status of 0-1 - Patients must be medically able to undergo surgical resection - Patients of child bearing potential must follow study specific precautions - Women that are lactating will not be excluded on the condition that they dispose their breast milk. - Adequate hematologic and biochemical parameters. Exclusion Criteria: - Prior treatment for pancreatic cancer. - Concurrent investigational treatments. - Unresectable pancreatic mass. - Neuroendocrine Histological pancreatic cancer - Distant Metastatic disease - Any condition that, in the option of the investigator, would compromise the well being of the patient or anything that would prevent the patient from meeting or performing study requirements



Primary Contact:

Principal Investigator
Theodore Pollock, DO
Southwestern Regional Medical Center, Inc.

Backup Contact:


Location Contact:

Tulsa, Oklahoma 74133
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 12, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.